Efficacy of Gamma Knife Radiosurgery for Recurrent High-Grade Gliomas with Limited Tumor Volume.

Autor: Cheon YJ; Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea., Jung TY; Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea., Jung S; Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea., Kim IY; Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea., Moon KS; Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea., Lim SH; Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea.
Jazyk: angličtina
Zdroj: Journal of Korean Neurosurgical Society [J Korean Neurosurg Soc] 2018 Jul; Vol. 61 (4), pp. 516-524. Date of Electronic Publication: 2018 Jul 01.
DOI: 10.3340/jkns.2017.0259
Abstrakt: Objective: This study aims to determine whether gamma knife radiosurgery (GKR) improves survival in patients with recurrent highgrade gliomas.
Methods: Twenty nine patients with recurrent high-grade glioma underwent 38 GKR. The male-to-female ratio was 10 : 19, and the median age was 53.8 years (range, 20-75). GKR was performed in 11 cases of recurrent anaplastic oligodendrogliomas, five anaplastic astrocytomas, and 22 glioblastomas. The median prescription dose was 16 Gy (range, 10-24), and the median target volume was 7.0 mL (range, 1.1-15.7). Of the 29 patients, 13 (44.8%) received concurrent chemotherapy. We retrospectively analyzed the progression-free survival (PFS) and overall survival (OS) after GKR depending on the Eastern Cooperative Oncology Group (ECOG) performance status (PS), pathology, concurrent chemotherapy, radiation dose, and target tumor volume.
Results: Starting from when the patients underwent GKR, the median PFS and OS were 5.0 months (range, 1.1-28.1) and 13.0 months (range, 1.1-75.1), respectively. On univariate analysis, the median PFS was significantly long in patients with anaplastic oligodendroglioma, ECOG PS 1, and target tumor volume less than 10 mL (p<0.05). Meanwhile, on multivariate analysis, patients with ECOG PS 1 and target tumor volume less than 10 mL showed improved PFS (p=0.043 and p=0.007, respectively). The median OS was significantly increased in patients with ECOG PS 1 and tumor volume less than 10 mL on univariate and multivariate analyses (p<0.05).
Conclusion: GKR could be an additional treatment option in recurrent high-grade glioma, particularly in patients with good PS and limited tumor volume.
Databáze: MEDLINE
Externí odkaz: